Per Walday CEO of PCI Biotech, said: "This first in man trial is an important step forward for the company. We are confident that our approach addresses one major challenge in oncology - how to deliver therapeutics with large enough loads to effectively destroy tumours while at the same time reducing the risk of damaging healthy cells. Bleomycin is ideal for demonstrating this - there is no doubt about its therapeutic potential, but until now delivery problems and associated toxicity have prevented the realisation of its full potential. We expect to have the first preliminary results of the trial early in 2010."

In addition, whilst our main initial focus is cancer, we strongly believe the PCI technology also has potential to improve the effect of emerging treatments such as gene therapy and therapies based on nanotechnology or on biotechnological principles. In particular, we are looking at siRNA through projects funded by EU and by the Norwegian Research Council."

pcibiotech.no/